Home » Stocks » MIST

Milestone Pharmaceuticals Inc. (MIST)

Stock Price: $5.70 USD -0.09 (-1.55%)
Updated Aug 3, 2021 1:51 PM EDT - Market open
Market Cap 170.12M
Revenue (ttm) n/a
Net Income (ttm) -46.14M
Shares Out 29.85M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $5.70
Previous Close $5.79
Change ($) -0.09
Change (%) -1.55%
Day's Open 5.79
Day's Range 5.52 - 5.99
Day's Volume 93,875
52-Week Range 5.09 - 10.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...

2 months ago - PRNewsWire

Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it's t...

2 months ago - Benzinga

- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the Am...

2 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...

2 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...

2 months ago - PRNewsWire

If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on I...

4 months ago - InvestorPlace

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

4 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

4 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

5 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

8 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

8 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...

9 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...

9 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

10 months ago - PRNewsWire

Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.

11 months ago - InvestorPlace

When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.

11 months ago - InvestorPlace

MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

11 months ago - PRNewsWire

Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Milestone Pharmaceuticals (MIST) news for Thursday includes new guidelines for a clinical study pushing MIST stock higher.

1 year ago - InvestorPlace

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update.

1 year ago - 24/7 Wall Street

MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

1 year ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in Milestone Pharmaceuticals.

1 year ago - Zacks Investment Research

Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 19th

Other stocks mentioned: AGFS, SYRS, UNFI
1 year ago - Zacks Investment Research

MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...

1 year ago - PRNewsWire

Milestone Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: AMAG, CPIX
1 year ago - Zacks Investment Research

Shares of small-cap Milestone Pharmaceuticals Inc (NASDAQ: MIST) were losing three-quarters of their value Tuesday on the back of a negative clinical readout.

1 year ago - Benzinga

Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.

1 year ago - The Motley Fool

About MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with ... [Read more...]

Industry
Biotechnology
Founded
2003
Stock Exchange
NASDAQ
Ticker Symbol
MIST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 13.80, which is an increase of 142.11% from the latest price.

Price Target
$13.80
(142.11% upside)
Analyst Consensus: Buy